LXRX Share Price Performance
US$1.15
-0.41 (-26.28%)
55.6% undervalued intrinsic discount
US$2.59
Fair Value
Price US$1.15
AnalystConsensusTarget US$2.59
Fair ValueUS$2.59
Share PriceUS$1.15
55.6% undervalued intrinsic discount
LXRX Community Narratives
AN
Fair Value US$2.59 55.6% undervalued intrinsic discount
Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
0users have liked this narrative
2users have commented on this narrative
20users have followed this narrative
Recent LXRX News & Updates
No updates
Lexicon Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.33
- Gross Margin
- -43.52%
- Net Profit Margin
- -206.43%
- Debt/Equity Ratio
- 43.3%
Lexicon Pharmaceuticals, Inc. Competitors
About LXRX
- Founded
- 1995
- Employees
- 103
- CEO
- WebsiteView website
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
U.S. Market Performance
- 7 Days: -0.2%
- 3 Months: 12.2%
- 1 Year: 22.4%
- Year to Date: 7.7%
The Communication Services sector gained 3.4% while the market remained flat over the last week. Meanwhile, the market is actually up 22% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading